Newsroom

LOTTE BIOLOGICS (CEO James Park) hosted a press briefing at Pacifico Yokohama during BIO Japan 2025, highlighting its achievements from the event and unveiling its differentiated growth strategy as a global ADC CDMO (Contract Development and Manufacturing Organization for Antibody-Drug Conjugates).

As Asia’s largest biotechnology event held annually since 1986, BIO Japan marked LOTTE BIOLOGICS’ third consecutive participation this year. The company expanded its exhibition booth to twice the size of last year’s, deepening engagement with potential clients, while CEO James Park took the stage as a keynote speaker to share the company’s strategic direction as a next-generation ADC CDMO.

■ Expanding Partnerships with Japan’s Top-Tier Biopharma Companies

LOTTE BIOLOGICS has accelerated collaboration with global clients, following the signing of three new manufacturing contracts earlier this year. The company continued its partnering efforts ahead of the event and held a series of meetings with prospective partners onsite in Yokohama.

A company representative said, “During BIO Japan, roughly 400 people visited our booth. In addition to scheduled partnering meetings, we conducted dozens of additional on-site meetings at the booth. There was strong interest in our Syracuse Bio Campus, and as plans for the Songdo Bio Campus take shape, we also received a variety of inquiries, including requests for site visits.”

■ “Redefining Pharma’s Future: CDMO Strategies for Next-Gen ADCs”

On the third day of the event, Friday, October 10, CEO James Park delivered a presentation titled “Redefining Pharma’s Future: CDMO Strategies for Next-Gen ADCs,” introducing LOTTE BIOLOGICS’ global growth strategy as a CDMO.

The presentation addressed evolving industry trends and market dynamics, including the shift toward on-shoring in the United States, changes in global supply chains, and the expansion of next-generation ADC platforms.

In particular, Park highlighted the company’s dual-site strategy between the U.S. and Korea as a key differentiator—leveraging its geopolitical advantage, extensive regulatory experience with over 62 global approvals (FDA, EMA, PMDA), and a highly experienced team averaging over 15 years in biopharmaceutical manufacturing. The synergy between the Songdo Bio Campus, serving as a large-scale manufacturing hub, and the Syracuse Bio Campus, providing one-stop services from antibodies to ADCs, was also emphasized.

The company further underscored its ADC development capabilities strengthened through diverse partnerships. While conventional ADCs have relied on standardized platforms, emerging modalities such as bispecific antibodies, dual-payload conjugates, and antibody-oligonucleotide conjugates (AOCs) are driving new innovation. LOTTE BIOLOGICS aims to deliver customized CDMO solutions through close collaboration with global biotech partners aligned with these industry shifts.

“Global demand for antibody therapeutics will continue to grow in both scale and sophistication,” said James Park, CEO of LOTTE BIOLOGICS. “With our proven manufacturing excellence and quality leadership, LOTTE BIOLOGICS will remain a trusted partner that adapts to evolving market needs and supports clients worldwide.”

LOTTE BIOLOGICS is scheduled to participate in CPHI Worldwide later this month, on October 28, and World ADC in November, with plans to further expand its footprint in the European market based on new contract achievements from BIO Japan 2025.